Giuseppe Morelli, M.D.
Clinical Professor
Department:
MD-GASTROENTERLOGY-LIVER
Business Phone:
(352) 273-9500
Business Email:
morelgj@medicine.ufl.edu
About Giuseppe Morelli
With over 20 years of practice, I would like all my patients, current and future, to understand my dedication to help them achieve their best quality of life. I am a clinical professor within the University of Florida Division of Gastroenterology, Heptatology and Nutrition. I treat patients with complications of portal hypertension and have a particular interest in patients who have complications of end stage liver disease. My role helps connect patients to the best possible treatment path available upon each patients presenting issues.
During medical school at Creighton University, I became fascinated by the physiologic changes that occur in the body in the setting of liver disease that led me later to become a hepatologist. I completed my internship, residency, fellowship in internal medicine, along with a fellowship in gastroenterology, at the Medical University of South Carolina.
When not at UF Health Shands Hospital or Malcom Randall VA Medical Center, I enjoy being a member of various academic liver societies, both domestically and internationally. Outside of medicine, I enjoy exploring family genealogy.
Teaching Profile
Courses Taught
2018
BME6010 Clinical Immersion
2018
MDC7200 Medicine Clerkship
2018
MDC7203 Senior Medicine Clerk
Board Certifications
-
GastroenterologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Gastroenterology
- Transplant Hepatology
Areas of Interest
- Autoimmune hepatitis
- Hepatitis B
- Hepatitis C
- Liver Transplant
- Liver biopsy
- Liver cancer – hepatocellular carcinoma
- Liver disease
- Liver disease – resources
- Primary biliary cirrhosis
Publications
2024
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations.
Hepatology (Baltimore, Md.).
79(5):1220-1238
[DOI] 10.1097/HEP.0000000000000646.
[PMID] 37934656.
2023
Change in Platelet Count after Transjugular Intrahepatic Portosystemic Shunt Creation: An Advancing Liver Therapeutic Approaches (ALTA) Group Study.
Journal of vascular and interventional radiology : JVIR.
34(8):1364-1371
[DOI] 10.1016/j.jvir.2023.04.015.
[PMID] 37100199.
2023
The impact of right atrial pressure on outcomes in patients undergoing TIPS, an ALTA group study.
Hepatology (Baltimore, Md.).
77(6):2041-2051
[DOI] 10.1097/HEP.0000000000000283.
[PMID] 36651170.
2022
Prognostic value of neutrophil-to-lymphocyte ratio in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt.
European journal of gastroenterology & hepatology.
34(4):435-442
[DOI] 10.1097/MEG.0000000000002295.
[PMID] 34750323.
2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Hepatology (Baltimore, Md.).
74(6):2952-2964
[DOI] 10.1002/hep.32053.
[PMID] 34255381.
2021
Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post-Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
27(3):329-340
[DOI] 10.1002/lt.25949.
[PMID] 33217178.
2021
Outcomes After TIPS for Ascites and Variceal Bleeding in a Contemporary Era-An ALTA Group Study.
The American journal of gastroenterology.
116(10):2079-2088
[DOI] 10.14309/ajg.0000000000001357.
[PMID] 34158464.
2021
Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.
European journal of gastroenterology & hepatology.
33(1):102-106
[DOI] 10.1097/MEG.0000000000001700.
[PMID] 32243349.
2020
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Journal of hepatology.
73(3):540-548
[DOI] 10.1016/j.jhep.2020.03.031.
[PMID] 32243960.
2020
Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation
American Journal of Clinical Oncology-Cancer Clinical Trials.
43(5):325-333
[DOI] 10.1097/COC.0000000000000678.
[PMID] 32079854.
2019
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.
Kidney international reports.
4(2):257-266
[DOI] 10.1016/j.ekir.2018.10.003.
[PMID] 30775622.
2019
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Gastroenterology.
157(6):1506-1517.e1
[DOI] 10.1053/j.gastro.2019.08.008.
[PMID] 31401140.
2019
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
17(4):774-783.e4
[DOI] 10.1016/j.cgh.2018.06.012.
[PMID] 29913280.
2019
Multidisciplinary Care for Cystic Fibrosis Liver Disease: Where Does the Adult Hepatologist Fit In?
Clinical liver disease.
14(5):187-190
[DOI] 10.1002/cld.845.
[PMID] 31879562.
2018
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.
Scientific reports.
8(1)
[DOI] 10.1038/s41598-018-21303-2.
[PMID] 29453451.
2018
Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease.
World journal of hepatology.
10(1):34-40
[DOI] 10.4254/wjh.v10.i1.34.
[PMID] 29399276.
2017
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Gut.
66(10):1844-1852
[DOI] 10.1136/gutjnl-2016-311609.
[PMID] 27418632.
2017
Pasteurella multocida Bacteremia and Peritonitis in a Patient With Cirrhosis: A Life-Threatening Case From a Prick of a Cactus.
Journal of investigative medicine high impact case reports.
5(3)
[DOI] 10.1177/2324709617726103.
[PMID] 28890902.
2017
Proton Pump Inhibitor Use Is Associated With an Increased Frequency of Hospitalization in Patients With Cystic Fibrosis.
Gastroenterology research.
10(5):288-293
[DOI] 10.14740/gr917w.
[PMID] 29118869.
2017
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Hepatology (Baltimore, Md.).
66(4):1083-1089
[DOI] 10.1002/hep.29256.
[PMID] 28498551.
2016
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
Gastroenterology.
150(2):419-29
[DOI] 10.1053/j.gastro.2015.10.013.
[PMID] 26497081.
2016
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
22(1):24-33
[DOI] 10.1002/lt.24366.
[PMID] 26519873.
2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Hepatology (Baltimore, Md.).
61(6):1793-7
[DOI] 10.1002/hep.27814.
[PMID] 25846014.
2014
Safety and Efficacy of New Daa-Based Therapy for Hepatitis C Post-Transplant: Interval Results From the Hcv-Target Longitudinal, Observational Study
Hepatology.
60(6)
2013
Ast-120 (Spherical Carbon Adsorbent) in Covert Hepatic Encephalopathy: Results of the Astute Trial
.
58
2013
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.
Liver international : official journal of the International Association for the Study of the Liver.
33(1):72-8
[DOI] 10.1111/liv.12013.
[PMID] 23107586.
2013
Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation.
Digestive diseases and sciences.
58(5):1403-9
[DOI] 10.1007/s10620-012-2521-9.
[PMID] 23306846.
2013
Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology.
43(7):757-64
[DOI] 10.1111/hepr.12019.
[PMID] 23193965.
2013
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Alimentary pharmacology & therapeutics.
37(1):91-7
[DOI] 10.1111/apt.12098.
[PMID] 23094860.
2013
Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma.
Oncology reports.
29(4):1259-67
[DOI] 10.3892/or.2013.2290.
[PMID] 23426976.
2012
Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation.
American journal of clinical oncology.
35(4):345-50
[DOI] 10.1097/COC.0b013e31821631f6.
[PMID] 21552101.
2011
A Sustained Viral Response Dramatically Improves Survival in Patients With Hepatitis C Infection After Liver Transplant
.
54
2011
Antiviral Effect of Sorafenib in Hcv Related Hepatocellular Carcinoma
Higher Education Policy.
54
2011
Hyperbilirubinemic Stain: Location and Extent in Dental Tissues
Journal of Clinical Pediatric Dentistry.
36:75-78
2011
Klatskin Tumor- Clinical Outcome and Prognostic Factors
Higher Education Policy.
54
2011
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Alimentary pharmacology & therapeutics.
33(2):235-42
[DOI] 10.1111/j.1365-2036.2010.04512.x.
[PMID] 21083674.
2011
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Alimentary pharmacology & therapeutics.
34(2):205-13
[DOI] 10.1111/j.1365-2036.2011.04697.x.
[PMID] 21605146.
2010
Mild Hepatic Encephalopathy (He) Assessed By the Repeatable Battery for the Assessment of Neuropsychological Status (Rbans) Is Highly Prevalent in Ambulatory Patients With Cirrhosis
.
52:S81-S82
2010
The Impact of Preservation Injury On Accelerated Hepatitis C Recurrence After Liver Transplantation
Higher Education Policy.
52
2010
The Impact of Transarterial Therapy in Recurrent Hepatocellular Carcinoma After Liver Transplant
Higher Education Policy.
52
2010
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Digestive diseases and sciences.
55(1):196-203
[DOI] 10.1007/s10620-009-0981-3.
[PMID] 19798576.
2009
False-positive “Cavernous Transformation” secondary to lymphatic filling in parenchymal hepatic CO(2) injection for portal vein visualization in TIPS procedures.
Journal of vascular and interventional radiology : JVIR.
20(5):600-5; quiz 571
[DOI] 10.1016/j.jvir.2009.01.032.
[PMID] 19328721.
2009
Fenofibrate Improves Liver Biochemistries in Primary Biliary Cirrhosis
Higher Education Policy.
50
2009
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Hepatology (Baltimore, Md.).
49(6):1838-46
[DOI] 10.1002/hep.22871.
[PMID] 19291790.
2009
Sustained Virological Response Rates in Patients Achieving Slow Response Or Complete Early Virological Response (Cevr) With Consensus Interferon (Cifn) and Ribavirin in the Direct Trial
.
50
2009
The natural history of hepatitis C cirrhosis after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
15(9):1063-71
[DOI] 10.1002/lt.21784.
[PMID] 19718647.
2009
Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
15(2):216-22
[DOI] 10.1002/lt.21666.
[PMID] 19177434.
2008
Cyclosporine Helps To Achieve a Higher Svr in Patients Receiving Peg-Interferon/Ribavirin for Recurrent Hepatitis C After Liver Transplantation: Final Analysis of a Randomized-Controlled Study
Journal of Hepatology.
48
[DOI] 10.1016/S0168-8278(08)60197-X.
2008
Factors predicting survival after transjugular intrahepatic portosystemic shunt creation: 15 years’ experience from a single tertiary medical center.
Journal of vascular and interventional radiology : JVIR.
19(11):1576-81
[DOI] 10.1016/j.jvir.2008.07.021.
[PMID] 18789725.
2008
Hepatocellular Carcinoma Is Associated With An Impaired Cd4 T Cell Immune Response
Journal of Hepatology.
48
[DOI] 10.1016/S0168-8278(08)60360-8.
2008
Is sonographic surveillance of polytetrafluoroethylene-covered transjugular intrahepatic portosystemic shunts (TIPS) necessary? A single centre experience comparing both types of stents.
Clinical radiology.
63(10):1142-8
[DOI] 10.1016/j.crad.2008.04.016.
[PMID] 18774362.
2008
Rapid-sequence endoscopic management of posttransplant anastomotic biliary strictures.
Gastrointestinal endoscopy.
67(6):879-85
[DOI] 10.1016/j.gie.2007.08.046.
[PMID] 18178206.
2008
The Natural History of Hcv-Related Cirrhosis After Liver Transplantation
Journal of Hepatology.
48
[DOI] 10.1016/S0168-8278(08)60003-3.
2008
Using Immune Functional Assay To Differentiate Acute Cellular Rejection From Recurrent Hepatitis C in Liver Transplant Patients
Higher Education Policy.
48
2007
Clinical Roundtable Monograph
Gastroenterology & Hepatology.
3(11)
2007
Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
5(7):803-8
[PMID] 17544879.
2006
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
12(1):51-7
[PMID] 16382464.
2006
Impact of implementation of the MELD Scoring system on the prevalence and incidence of chronic liver disease following liver transplantation
Liver Transplantation.
12(5):754-761
[DOI] 10.1002/lt.20686.
[PMID] 16528716.
2006
Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosis.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
12(2):306-9
[PMID] 16447188.
2005
Short recovery time after percutaneous liver biopsy: should we change our current practices?
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
3(9):926-9
[PMID] 16234032.
2003
Financial and Clinical impact of vancomycin-resistant enterococcus (vre) in liver transplant recipients: a double matched controlled study
Journal of Gastrointestinal Surgery.
7(2)
[DOI] 10.1016/S1091-255X(02)00202-0.
2002
U.S. veterans’ experience with rebetron in a nonstudy environment: success or failure?
The American journal of gastroenterology.
97(9):2379-82
[PMID] 12358260.
2001
Endoscopic treatment of post-liver transplantation biliary leaks with stent placement across the leak site.
Gastrointestinal endoscopy.
54(4):471-5
[PMID] 11577309.
2001
Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.
The American journal of gastroenterology.
96(10):2957-61
[PMID] 11693332.
Grants
Sep 2021
ACTIVE
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
Role: Principal Investigator
Funding: MEDPACE
via AXCELLA HEALTH INC
Jun 2020
– Feb 2022
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients with Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
Role: Principal Investigator
Funding: CATO RESEARCH
via TERNS
Mar 2020
ACTIVE
ALTA TIPS: Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group in the use of TIPS for the management of Portal Hypertension
Role: Principal Investigator
Funding: NORTHWESTERN UNIV
via W L GORE AND ASSOCIATES INC
Mar 2018
– Oct 2023
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via CONATUS PHARMACEUTICALS
Jan 2016
– Mar 2022
Prioritize Study
Role: Other
Funding: PATIENT-CENTERED OUTCOMES RES INST
Jan 2016
– Dec 2018
A PHASE 3, GLOBAL, MULTICENTER, RANDOMIZED, OPEN LABEL STUDYTO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATA
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via GILEAD SCIENCES
Jan 2016
– Dec 2018
A PHASE 3, GLOBAL, MULTICENTER, RANDOMIZED, OPEN LABEL STUDYTO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATA
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via GILEAD SCIENCES
Dec 2015
– Dec 2018
A PHASE 2,PILOT STUDY OF JKB-122 TO ASSESS LIVER TESTS (ALT)IN AUTOIMMUNE HEPATITIS PATIENTS WHO ARE REFRACTORY OR …
Role: Principal Investigator
Funding: DUKE UNIVERSITY
via TAIWANJ PHARMACEUTICALS CO LTD
Dec 2015
– Aug 2016
Gilead 367-1170 'A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks..
Role: Principal Investigator
Funding: GILEAD SCIENCES
Nov 2015
– Mar 2019
A PHASE II RANDOMIZED OPEN LABEL CLINICAL TRIAL TO STUDY THEEFFICACY AND SAFETY OF THE COMBINATION REGIMON OF MK-3682B
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Oct 2015
– Oct 2018
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks….
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via GILEAD SCIENCES
Sep 2015
– Sep 2018
A Phase 3, Global, Multicenter, Randomized, double blind placebo controlled study to investigate the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed dose combination for 12 weeks in direct acting antiviral-experienced
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via GILEAD SCIENCES
Aug 2015
– Aug 2018
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis
Role: Principal Investigator
Funding: PPD DEVELOPMENT
via GALECTIN THERAPEUTICS INC
Jun 2015
– Jun 2018
Open-Label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir
Role: Principal Investigator
Funding: ABBVIE
Apr 2015
– Apr 2018
Clinical evaluation of the Xpert HCV VL.Assay
Role: Principal Investigator
Funding: SC LIVER RESEARCH CONSORTIUM
via Cepheid
Jan 2015
– Dec 2017
Immuron "A phase II, randomized, doduble-blind, placebo-controlled study of IMM-124E for patients with non-alcoholic steatohepatitis"
Role: Principal Investigator
Funding: IMMURON
Nov 2014
– Nov 2017
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection
Role: Principal Investigator
Funding: GILEAD SCIENCES
Nov 2014
– Sep 2015
Hyperion HPN-100-022 "AN OBSERVATIONAL STUDY TO ASSESS DOCUMENTATION OF HEPATIC ENCEPHALOPATHY IN CLINICAL PRACTICE"
Role: Principal Investigator
Funding: HYPERION THERAPEUTICS INC
Nov 2014
ACTIVE
PAYROLL OPERATING ACCOUNT
Role: Principal Investigator
Funding: 214 OPERATING ACCOUNT
Oct 2014
– Oct 2017
A Randomized, Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study"
Role: Principal Investigator
Funding: PPD DEVELOPMENT
via GILEAD SCIENCES
Aug 2014
– Aug 2017
Gilead GS-US-342-1139" A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 FDC for 12 Wks with Sofos and RBV for 12 Wks in Subjects with Chronic Genotype 2 HCV Infection
Role: Principal Investigator
Funding: PHARMACEUTICAL RES ASSO
via GILEAD SCIENCES
Aug 2014
– Aug 2017
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir with or without Ribavarin (RBV) in Treatment-Na?ve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Role: Principal Investigator
Funding: ABBVIE
Aug 2014
– Aug 2017
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects with Liver Cirrhosis
Role: Principal Investigator
Funding: SC LIVER RESEARCH CONSORTIUM
Jul 2014
– Jul 2017
Gilead GS-US-342-1138" A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV"
Role: Principal Investigator
Funding: GILEAD SCIENCES
Jun 2014
– Jun 2017
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection"
Role: Principal Investigator
Funding: GILEAD SCIENCES
Nov 2013
– Nov 2016
'Open-Label, Study to Evaluate Eff and Safety of Sofosbuvir/Ledipasvir FDC + RBV for 12 Wks in Chronic Geno 1 HCV Subjects Who Participated in Prior Gilead-Sponsored HCV Tx study'
Role: Principal Investigator
Funding: GILEAD SCIENCES
Aug 2013
– Aug 2016
RNLC2131 A RAND, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE SOLID DISPERSION (SSD) TABLETS FOR THE PREV OF COMPLICATIONS IN SUBJECTS WITH EARLY DECOMP LIVER CIRRHOSIS
Role: Principal Investigator
Funding: SALIX PHARMACEUTICALS
Apr 2013
– Apr 2016
GS-US-342-0109 'A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment Experienced Subjects with Chronic HCV Infection'
Role: Principal Investigator
Funding: GILEAD SCIENCES
Apr 2013
– Apr 2016
GS-US-342-0102 'A PHASE 2, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT-NAIVE SUBJECTS WITH CHRONIC HCV INFECTION'
Role: Principal Investigator
Funding: GILEAD SCIENCES
Feb 2013
– Dec 2015
RFHE4044 'A MULTICENTER,RANDOMIZED,OPEN-LABEL, ACTIVE-CONTROLLED,TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF RIFAXIMIN 550MG WITH AND WITHOUT LACTULOSE IN SUBJECTS WITH A HISTORY OF RECURRENT OVERT HE'
Role: Principal Investigator
Funding: SALIX PHARMACEUTICALS
Oct 2011
ACTIVE
HCV-TARGET Primary Operating Project with subprojects
Role: Project Manager
Funding: UF DIV OF SPONSORED RESEARCH
Education
Fellowship – Gastroenterology
2001
·
Medical University of South Carolina
Fellowship – Internal Medicine
1998
·
Medical University of South Carolina
Residency – Internal Medicine
1997
·
Medical University of South Carolina
Internship – Internal Medicine
1995
·
Medical University of South Carolina
Medical Degree
1994
·
Creighton University
Contact Details
Phones:
- Business:
- (352) 273-9500
Emails:
- Business:
- morelgj@medicine.ufl.edu
Addresses:
- Business Mailing:
-
2004 MOWRY RD
GAINESVILLE FL 32610 - Business Street:
-
2004 MOWRY RD
GAINESVILLE FL 32610